Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2017 07:00 ET | Source: Kalytera Therapeutics, Inc.

Kalytera Announces Management Changes and Expansion of Leadership Team

SAN FRANCISCO and TEL AVIV, Israel, June 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid...
May 31, 2017 07:00 ET | Source: Kalytera Therapeutics, Inc.

Kalytera Reports First Quarter 2017 Financial Results

VANCOUVER, British Columbia, May 31, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for...
May 26, 2017 07:30 ET | Source: Kalytera Therapeutics, Inc.

Kalytera Announces Changes to its Board of Directors

VANCOUVER, British Columbia, May 26, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for...
May 02, 2017 08:30 ET | Source: Kalytera Therapeutics, Inc.

Kalytera Reports FY 2016 Results; Provides Corporate Update and 2017 Outlook

VANCOUVER, British Columbia, May 02, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF), a clinical-stage biopharmaceutical company developing cannabinoid-derived...
April 25, 2017 08:30 ET | Source: Kalytera Therapeutics, Inc.

Kalytera Identifies Sites for Planned GvHD Clinical Trials; Company’s Research Gains Support at EBMT 2017

VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived...
April 17, 2017 08:30 ET | Source: Kalytera Therapeutics, Inc.

Kalytera Applies for $5 Million R&D Grant from IIA

VANCOUVER, British Columbia, April 17, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY), a clinical stage biopharmaceutical company developing next generation cannabinoid-derived...
March 17, 2017 08:30 ET | Source: Kalytera Therapeutics, Inc.

Kalytera Therapeutics Appoints Pini Ben-Elazar to Board of Directors

VANCOUVER, British Columbia, March 17, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) today announced that Mr. Pini Ben-Elazar has been appointed to Kalytera’s Board of Directors. ...
February 22, 2017 09:18 ET | Source: Kalytera Therapeutics, Inc.

Kalytera Therapeutics Announces Encouraging Results of a Phase 2a Clinical Study for the Treatment of Acute Graft versus Host Disease

VANCOUVER, British Columbia, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) is pleased to announce encouraging results from a Phase 2a study evaluating the...
February 16, 2017 16:30 ET | Source: Kalytera Therapeutics, Inc.

Kalytera Therapeutics to Announce Phase 2a Clinical Study Results Investigating CBD for the Treatment of Acute Graft versus Host Disease

VANCOUVER, British Columbia, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) will announce the results of a Phase 2a study investigating the safety and...
February 16, 2017 08:30 ET | Source: Kalytera Therapeutics, Inc.

Kalytera Therapeutics Completes Acquisition of Talent Biotechs

Lead program in Graft versus Host Disease (“GvHD”), a life-threatening condition that can occur following stem cell or bone marrow transplantationFour Phase 2 clinical studies evaluating CBD in the...